WILMINGTON, Mass., March 26, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB: IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today reported the
shipment of approximately $500,000 in
explosives trace detection systems in Latin America, most of which were sold to a
major international airline in Latin
America.
"Implant Sciences continues to expand its market share in the
Latin American aviation security space. We believe that the
combination of our superior performance and value proposition is
the impetus behind this success, which could also set the stage for
follow-on orders from these customers," stated Dr. Darryl Jones, Implant Sciences' Global Vice
President of Sales and Marketing. "We are seeing a
significant increase in demand for our products since our recent
checkpoint certifications from the US Transportation Security
Administration (TSA) and the European Civil Aviation Conference
(ECAC)."
"Our QS-B220 is specifically designed to meet the needs of
aviation-related applications, including passenger, baggage, and
cargo screening. As the only non-radioactive ETD in the world to
pass the latest testing protocols of both TSA and ECAC, the QS-B220
is becoming the ETD of choice for a larger number of purchasers in
the aviation security market," added Dr. Bill McGann, CEO of Implant Sciences.
About the QS-B220 Desktop Explosives and Drugs Trace
Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly
detect and identify trace amounts of a wide variety of military,
commercial, and homemade explosives as well as illicit drugs. With
significantly lower maintenance requirements than competing
systems, the QS-B220 can be deployed for a lower total cost
of ownership than other approved products. Featuring a radioactive
material-free design, push-button maintenance and diagnostics, and
a patented inCalâ„¢ internal automatic calibration system, the
QS-B220 brings new levels of performance and convenience to desktop
trace detection users with unsurpassed ease of use.
About the QS-H150 Handheld Explosives Trace Detector
The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology,
providing fast, accurate detection of trace amounts of a wide
variety of military, commercial, and homemade explosives. Built
with no radioactive materials and featuring a low-maintenance,
self-calibrating, and self-clearing design, the QS-H150 provides
very high levels of operational availability. The QS-H150 has been
proven to perform well in a wide variety of temperatures and
challenging environments, from humid jungles to dry, sand swept
deserts.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The Company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 50 countries worldwide. The
Company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any related statements of management and
representatives of Implant Sciences Corporation (the "Company")
contain "forward-looking statements" as that term is defined in the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as "plan," "project," "potential," "seek,"
"may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate" or "continue" are intended to identify
forward-looking statements. Such statements are based on
management's current expectations and are subject to significant
risks and uncertainties that could cause the Company's actual
results to differ materially from the forward-looking statements.
Such risks and uncertainties include, but are not limited to, the
risks that the Company will be required to repay all of its
indebtedness to secured lenders by the due dates; the risk that if
the Company is unable to satisfy its obligations to its secured
lenders and to raise additional capital to fund operations, lenders
may seize the Company's assets and its business may fail; the
Company continues to incur substantial operating losses and may
never generate recurring revenue or profitability; the Company's
independent registered public accounting firm has expressed
substantial doubt as to the Company's ability to continue as a
going concern; there is no guaranty that the Transportation
Security Administration (TSA) or any other U.S. or foreign
government and law enforcement agencies or commercial consumers
will purchase any of the Company's explosives detection products or
that any new products which the Company may develop will be
accepted by the TSA or by such other governments, agencies or
consumers; economic, political and other risks associated with
international sales and operations could adversely affect the
Company's sales; liability claims related to the Company's products
or the Company's handling of hazardous materials could damage the
Company's reputation and have a material adverse effect on the
Company's financial results; the Company's business is subject to
intense competition; the Company's markets are subject to rapid
technology change and the Company's viability will depend on its
ability to develop and introduce new products; the Company may not
be able to retain its management and key employees or identify,
hire and retain additional personnel as needed; the Company may not
be able to enforce its patent and other intellectual property
rights or operate without infringing on the proprietary rights of
others; and other risks and uncertainties described in the
Company's filings with the Securities and Exchange Commission,
including our most recent Forms 10-K, 10-Q and 8-K. Such statements
are based on management's current expectations and assumptions
which could cause the actual results to differ materially from
those anticipated in the forward-looking statements. The
Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by applicable
law.
Contact:
Implant Sciences Corporation
Company Contact:
978-752-1700 x 116
or
Investor Contact:
Laurel Moody
646-810-0608
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/major-international-airline-in-latin-america-adopts-qs-b220-300056319.html
SOURCE Implant Sciences Corporation